VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CERS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CERSCerus Corporation
$2.99$599M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCERSBalance Sheet

Cerus Corporation (CERS) Balance Sheet

29Y historyFree accessUpdated daily

The company's financial stability is strained by a debt-to-equity ratio of 0.95 and a stagnant retained earnings balance of negative $1.1 billion, indicating limited internal capital generation.

CERS Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97
Total Current Assets175.34M174.38M152.02M144.44M170.14M187.1M183.43M128.11M146.9M89.9M94.11M130.44M74.87M78.15M44M39.74M41.76M32.36M42.04M73.9M102.74M51.01M99.87M115.75M67.25M125.06M91.04M40.7M20.1M26.2M
Cash & Short-Term Investments80.42M82.88M80.45M65.85M102.15M129.36M133.59M85.72M117.58M60.7M71.63M107.88M51.29M57.68M26.7M25.78M30.01M19.93M22.58M56.85M93.42M45.8M95.33M110.01M64.32M123.46M90.26M40.4M6.2M11.6M
Cash Only27.85M19.96M20.27M11.65M35.59M48.76M36.59M34.99M28.86M13.68M22.56M71.02M22.78M29.48M26.7M25.5M28.95M17.29M10.3M19.63M46.29M5.78M39.17M23.16M22.43M64.5M71.87M3.5M6.2M11.6M
Short-Term Investments52.58M62.92M60.19M54.2M66.57M80.6M97M50.73M88.72M47.01M49.07M36.86M28.51M28.19M0287K1.06M2.64M12.28M37.23M47.13M40.02M56.16M86.84M41.88M58.96M18.39M36.9M00
Accounts Receivable29.32M30.37M29.78M35.5M34.43M25.13M21.17M16.88M8.75M12.41M6.87M5.79M5.49M6.13M4.44M6.1M4.79M3.63M7.15M7.77M5.28M5.2M4.54M5.74M2.93M1.6M267K004.4M
Days Sales Outstanding50.9353.7860.2982.8777.5470.0984.0582.5552.45104.0167.4261.854.9356.3744.267.3475.6973.58158.14256.8654.1677.88119.04216.92125.97128.752.65--232.75
Inventory61.12M56.1M38.15M39.87M29M26.79M23.25M19.49M13.54M14.46M12.53M10.81M14.96M13.06M10.18M6.44M5.96M7.71M11.11M7.06M1.83M0-4.53M-5.74M-2.88M00000
Days Inventory Outstanding201.59213.65172.45207.98141.23154.07206.23212.87156.22234.2225.37168.19257.79210.95180.23126.9180.5223.61419.4493.04434.16---------
Other Current Assets4.47M5.03M3.64M3.22M4.56M00002.33M1.8M4.75M1.93M442K2.04M605K0000000000512K300K13.9M10.2M
Total Non-Current Assets47.57M47.48M48.9M53.31M47.95M50.4M37.98M37.43M16.56M8.35M9.37M9.03M6.9M5.23M4.92M5.63M6.41M2.13M5.3M4.31M13.07M7.66M2.21M2.71M5.7M3.2M3.12M1.1M800K1.1M
Property, Plant & Equipment18.7M19.33M15.54M19.35M23.48M25.18M26.99M29.02M8.13M2.12M2.98M3.55M3.78M2.19M1.7M2.03M2.39M1.22M1.84M1.32M1.63M1.24M947K2.55M5.55M3.01M2.99M1M700K1M
Fixed Asset Turnover12.69x10.66x11.60x8.08x6.90x5.20x3.41x2.57x7.49x20.56x12.46x9.64x9.65x18.12x21.61x16.26x9.67x14.78x8.95x8.35x21.87x19.73x14.69x3.79x1.53x1.51x0.62x2.40x4.14x6.90x
Goodwill1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M1.32M0000000000000
Intangible Assets0000000132K334K536K738K940K1.14M1.34M1.55M1.75M1.95M0000000000000
Long-Term Investments1.14M00000002.73M247K-150K-122K-115K-89K-62K0-189.3M02.33M2M11M6M1.18M0000000
Other Non-Current Assets27.55M26.83M32.04M32.64M23.15M23.9M9.68M6.96M6.78M4.38M4.33M3.23M665K378K363K532K756K-181.19M1.12M2.98M11.45M6.42M85K156K152K188K127K100K100K100K
Total Assets222.91M221.86M200.92M197.75M218.09M237.5M221.41M165.53M163.46M98.24M103.48M139.47M81.77M83.38M48.92M45.37M48.17M34.49M47.34M78.21M115.82M58.66M102.08M118.46M72.95M128.26M94.16M41.8M20.9M27.3M
Asset Turnover0.99x0.93x0.90x0.79x0.74x0.55x0.42x0.45x0.37x0.44x0.36x0.25x0.45x0.48x0.75x0.73x0.48x0.52x0.35x0.14x0.31x0.42x0.14x0.08x0.12x0.04x0.02x0.06x0.14x0.25x
Asset Growth %46.62%10.42%1.6%-9.33%-8.17%7.26%33.76%1.27%66.38%-5.06%-25.81%70.56%-1.93%70.45%7.83%-5.81%39.65%-27.14%-39.47%-32.47%97.44%-42.53%-13.83%62.4%-43.13%36.21%125.27%100%-23.44%-
Total Current Liabilities107.38M100.8M63.61M67.52M117.06M78.56M59.97M50.34M52.68M23.13M26.89M21.89M29M39.42M25.61M21.11M19.7M12.91M12.9M18.32M14.81M23.32M76.09M65.94M16.76M16.45M12.16M8.7M19.6M4.8M
Accounts Payable028.01M21.7M23.84M33M35.61M24.21M22.18M18.59M10.97M8.59M5.22M9.88M5.67M7.19M4.68M3.23M4.42M7.96M10.11M6.67M2.09M1.48M4.64M10.56M8.25M6.07M2.01M14.1M1.3M
Days Payables Outstanding75.29106.6698.07124.38160.71204.76214.73242.3214.55177.78154.4381.15170.3391.63127.2392.1697.87128.33300.63705.631.58K------3.49K-1.22K-7.35K-677.86
Short-Term Debt55.54M46.25M19.3M20M56.16M14.7M8.52M5.02M7.86M06.93M2.96M03.37M4.83M2.52M1.75M0030K84K4.89M34.5M55.85M35K31K32K31K0100K
Deferred Revenue (Current)7.49M1.27M1.4M2M589K673K577K570K498K445K149K554K399K181K77K111K248K345K445K1.5M586K11.13M13.22M614K718K927K0000
Other Current Liabilities50.12M25.27M11.94M11.82M17.58M18.51M16M12.7M14.96M4.34M4.12M7.94M14.98M27.68M10.83M10.01M8.46M2.74M445K0586K022.09M0006.05M6.66M5.5M3.4M
Current Ratio1.63x1.73x2.39x2.14x1.45x2.38x3.06x2.55x2.79x3.89x3.50x5.96x2.58x1.98x1.72x1.88x2.12x2.51x3.26x4.03x6.94x2.19x1.31x1.76x4.01x7.60x7.49x4.68x1.03x5.46x
Quick Ratio1.06x1.17x1.79x1.55x1.21x2.04x2.67x2.16x2.53x3.26x3.03x5.46x2.07x1.65x1.32x1.58x1.82x1.91x2.40x3.65x6.81x2.19x1.37x1.84x4.18x7.60x7.49x4.68x1.03x5.46x
Cash Conversion Cycle177.23160.77134.67166.4758.0719.475.5453.11-5.89160.43138.35148.83142.38175.797.21102.07158.32168.86276.9244.27-1.09K---------
Total Non-Current Liabilities47.24M56.09M80.41M76.78M32.47M73.33M57.63M58.15M26.26M36.17M18.8M22.81M11.07M1.16M4.2M5.94M4.73M130K163K2K32K68K4.5M016K5.05M84K100K5M0
Long-Term Debt9.38M40.55M64.86M59.8M13.64M54.72M39.59M39.41M22.01M29.8M12.44M16.85M9.87M02.9M4.7M3.13M000004.5M0051K84K115K00
Capital Lease Obligations32.23M10.15M11.66M13.75M15.33M16.26M16.87M18.41M000000006K15K02K32K68K0016K51K84K000
Deferred Tax Liabilities000000000-100K150K122K115K89K62K000000000000000
Other Non-Current Liabilities37.86M5.39M3.89M3.24M3.5M2.34M1.17M327K4.25M6.38M6.21M5.8M1.08M1.07M1.24M1.24M1.59M115K163K0000004.95M-84K-15K00
Total Liabilities154.62M156.89M144.02M144.3M149.53M151.88M117.61M108.48M78.94M59.3M45.69M44.7M40.06M40.59M29.81M27.05M24.43M13.04M13.06M18.32M14.85M23.39M80.59M65.94M16.78M21.5M12.24M8.8M19.6M4.8M
Total Debt64.92M96.95M98.1M96M87.24M87.59M66.89M64.45M29.87M29.8M19.38M19.87M9.87M3.37M7.72M7.22M4.89M24K032K116K4.96M39M55.85M51K82K116K100K5M100K
Net Debt37.07M76.98M77.83M84.35M51.65M38.83M30.3M29.46M1.01M16.11M-3.19M-51.15M-12.91M-26.12M-18.97M-18.28M-24.05M-17.26M-10.3M-19.59M-46.17M-819K-169K32.69M-22.38M-64.42M-71.76M-3.4M-1.2M-11.5M
Debt / Equity0.95x1.49x1.72x1.80x1.27x1.02x0.64x1.13x0.35x0.77x0.34x0.21x0.24x0.08x0.40x0.39x0.21x0.00x-0.00x0.00x0.14x1.81x1.06x0.00x0.00x0.00x0.00x3.85x0.00x
Debt / EBITDA-4.09x-----------------------------
Net Debt / EBITDA-2.34x-----------------------------
Interest Coverage-2.63x-4.36x-1.34x-3.45x-6.26x-9.98x-14.90x-11.05x-13.31x-17.76x-24.66x-33.92x-63.37x-82.28x-27.45x-16.47x-23.41x-79.88x-2917.10x-----------
Total Equity68.29M64.97M56.9M53.44M68.56M85.62M103.81M57.05M84.52M38.94M57.79M94.77M41.71M42.8M19.11M18.31M23.73M21.45M34.28M59.89M100.97M35.27M21.49M52.53M56.17M106.75M81.92M33M1.3M22.5M
Equity Growth %61.86%14.18%6.46%-22.05%-19.92%-17.52%81.95%-32.5%117.05%-32.61%-39.02%127.2%-2.54%123.98%4.34%-22.83%10.65%-37.43%-42.76%-40.69%186.24%64.15%-59.09%-6.48%-47.39%30.31%148.25%2438.46%-94.22%-
Book Value per Share0.350.340.310.300.390.500.630.410.640.360.570.980.540.630.350.380.590.621.061.883.531.470.972.713.557.076.262.970.142.69
Total Shareholders' Equity68.29M64.22M56.15M52.65M67.61M84.62M103.81M57.05M84.52M38.94M57.79M94.77M41.71M42.8M19.11M18.31M23.73M21.45M34.28M59.89M100.97M35.27M21.49M52.53M56.17M106.75M81.92M33M1.3M22.5M
Common Stock200K192K186K181K177K174K168K144K136K115K103K99K80K72K56K51K47K39K33K32K32K23K22K22K16K16K14K000
Retained Earnings-1.08B-1.08B-1.07B-1.04B-1.01B-964.34M-909.97M-850.11M-778.87M-721.3M-660.72M-597.81M-541.94M-503.19M-459.85M-443.94M-426.95M-410.04M-385.91M-356.73M-311.42M-306.64M-319.71M-288.55M-230.29M-173.09M-123.73M-87.5M-64.4M-34.9M
Treasury Stock000000000000000000000000000000
Accumulated OCI-323K-156K-400K-1.27M-2.79M-149K674K114K-281K-97K103K7.29M-31K7K-8.32M0108K58K212K75K-22K-295K-324K-10.32M-7.1M-4.6M-3.53M-2.9M-2.3M-1.7M
Minority Interest733K741K751K794K952K998K000000000000000000000000

Key Metrics

Growth RegimeExpanding
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Capital Erosion Amidst Operational Expansion

As reported in recent financial statements, Cerus's equity base has remained under pressure, with retained earnings stagnating at negative $1.1 billion, signaling that the company's ongoing expansion efforts are failing to generate the internal capital necessary to offset persistent operational losses and sustain its long-term growth trajectory.

The persistent negative retained earnings suggest that the company is effectively consuming its equity to fund R&D and commercialization efforts. Investors should monitor whether the recent revenue growth can eventually translate into a stabilization of the equity base or if further capital raises will be required.

Leverage Constraints and Refinancing Risks

Based on reported figures, Cerus's debt-to-equity ratio has fluctuated significantly, reaching 0.95 in 2026Q1, which indicates that the company relies heavily on debt financing to bridge the gap between its current cash burn and the long-term potential of its pathogen reduction technology pipeline.

The reliance on debt in a pre-profitability state creates a precarious financial position, particularly as the company approaches maturity on its obligations. This leverage appears to be a necessity-driven strategy rather than a strategic choice, which may limit management's flexibility in future capital allocation decisions.

Tightening Cash Runway and Buffer

According to recent SEC filings, Cerus's cash position of $27.9 million as of 2026Q1, while improved from the previous quarter, remains dangerously thin relative to its ongoing operating expenses, suggesting that the company lacks a sufficient buffer to withstand unexpected shocks or delays in its clinical trial milestones.

The current ratio of 1.63 indicates that while short-term assets cover current liabilities, the quality of these assets—largely tied to inventory and receivables—may be less liquid than the headline number suggests. This liquidity profile warrants further investigation into the company's ability to fund operations without dilutive financing.

Hidden Risks in Asset Composition

Data from the balance sheet reveals that the company's asset base is heavily weighted toward non-cash items, with net PPE of $18.7 million, which may be subject to impairment if the commercial adoption of the INTERCEPT system fails to meet the aggressive growth targets currently priced in.

The reliance on specialized hardware and inventory creates a risk of obsolescence, particularly if regulatory requirements or clinical standards shift. Investors should be wary that the book value of these assets may not reflect their true realizable value in a distressed scenario, potentially overstating the company's tangible net worth.

CERS — Frequently Asked Questions

Quick answers to the most common questions about buying CERS stock.

What are the total assets of Cerus Corporation (CERS)?

As of 2025, Cerus Corporation (CERS) had total assets of $221.9M including $174.4M in current assets.

How much debt does Cerus Corporation (CERS) have?

Cerus Corporation (CERS) carries total debt of $96.9M, offset by $82.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Cerus Corporation?

Cerus Corporation (CERS) has total shareholders' equity (book value) of $64.2M ($0.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Cerus Corporation's current ratio and liquidity?

Cerus Corporation (CERS) reported a current ratio of 1.73x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.